Biogen Announces the Expiration Date Results of Its Cash Tender Offer

CAMBRIDGE, Mass., Feb. 11, 2021 (WORLD NEWSWIRE) — Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today revealed the expiration date outcomes of its formerly revealed deal to acquire for money (the “Cash Offer”) its exceptional 5.200% Senior Notes due 2045 (the “Notes”), amounting to $1.75 billion in aggregate principal quantity, on the terms and based on the conditions state in the Deal to Purchase outdated February 4, 2021 (the “Offer to Purchase”) and the accompanying accreditation of eligibility to take part in the Money Deal, the guidelines for such accreditation and the notification of ensured shipment (jointly, the “Cash Offer Documents”).

The Money Deal ended at 5:00 p.m., New york city City time, on February 10, 2021 (the “Expiration Date”). The “Settlement Date” will be immediately following the Expiration Date and is anticipated to be February 16, 2021.

The following table state the aggregate principal quantity of Notes validly tendered and not validly withdrawn at or prior to the Expiration Date, consisting of the aggregate principal quantity tendered pursuant to the ensured shipment treatments explained in the Deal to Purchase at or prior to the Expiration Date, which Biogen anticipates to accept on the Settlement Date in connection with the Money Deal.

Title of Notes to be Exchanged Principal Quantity Impressive since the Expiration Date CUSIP/ISIN Principal Quantity of Notes Tendered since the Expiration Date for Purchase(1) Principal Quantity of Notes Tendered Pursuant to Surefire Shipment Treatments
5.200% Senior Notes due 2045 $1,750,000,000 09062X AD5 / US09062XAD57 $8,907,000 $2,864,000

(1)      Omitting Notes tendered pursuant to ensured shipment treatments.

These quantities are based upon info supplied by the tender representative since the Expiration Date. Upon the terms and based on the conditions state in the Money Deal Files, on the Settlement Date, Qualified Holders (as specified listed below) who (i) validly tendered and did not validly withdraw Notes at or prior to the Expiration Date or (ii) provided a legitimate notification of ensured shipment and all other needed files at or prior to the Expiration Date and tender their Notes at or prior to 5:00 p.m., New york city City time, on February 12, 2021 (the “Guaranteed Delivery Date”), pursuant to specific ensured shipment treatments, and whose Notes are accepted for purchase by Biogen, will get the Tender Factor to consider (as specified in the Deal to Purchase), along with accumulated and overdue interest on such Old Notes from the last interest payment date to, however leaving out, the Settlement Date.

Based upon the foregoing tenders, Biogen anticipates to pay in money Tender Factor to consider of roughly $16 million in the aggregate, presuming that all Notes tendered pursuant to the ensured shipment treatments will hurt at or prior to the Surefire Shipment Date. The real aggregate quantity of money that will be paid on the Settlement Date undergoes alter based upon shipments under the ensured shipment treatments and last recognition of tenders.

Biogen will provide money as payment for Notes accepted for purchase in the Money Deal on the Settlement Date. Interest on the Notes accepted for purchase in the Money Deal, consisting of those tendered pursuant to the ensured shipment treatments, will stop to accumulate on the Settlement Date.

Biogen likewise revealed today the expiration date outcomes of its different exchange deal (the “Exchange Offer”), made just to Ineligible Holders (as specified listed below), to exchange Notes for a brand-new series of senior notes and money.

The total terms of the Money Deal are stated in the Money Deal Files, which were dispersed to Qualified Holders in connection with the Money Deal. The conditions to the Money Deal have actually been pleased since the Expiration Date.

The Money Deal was made just to “Eligible Holders,” which are holders of Notes that accredited that they are not “qualified institutional buyers”, as that term is specified in Guideline 144A under the U.S. Securities Act of 1933, as changed (the “Securities Act”), which are not non-U.S. individuals, as that term is specified in Guideline 902 under the Securities Act, situated beyond the U.S. within the significance of Policy S under the Securities Act (unless they are “retail investors” in the European Economic Location or in the UK, or financiers in any province or area of Canada that are people or that are organizations or other entities that do not certify as both “accredited investors” and “permitted clients”), as more totally explained in the Deal to Purchase. All holders of Notes who are not Qualified Holders are “Ineligible Holders”.

Just Qualified Holders who sent a legitimate eligibility certificate were licensed to take part in the Money Deal.

International Shareholder Providers Corporation is functioning as the tender representative and info representative for the Money Deal. Concerns or ask for support connected to the Money Deal might be directed to International Shareholder Providers Corporation (866) 470-3900 (U.S. toll-free) or (212) 430-3774 (gather for banks and brokers), or by means of email at contact@gbsc-usa.com. You might likewise call your broker, dealership, business bank, trust business or other candidate for support worrying the Money Deal.

This press release is not a deal to purchase or a solicitation of a deal to offer any of the securities explained herein. The Money Deal was made entirely by the Money Deal Files and just to such individuals and in such jurisdictions as was allowed under relevant law and the terms of the Money Deal.

About Biogen

At Biogen, our objective is clear: we are leaders in neuroscience. Biogen finds, establishes and provides around the world ingenious treatments for individuals living with severe neurological and neurodegenerative illness along with associated restorative adjacencies. Among the world’s very first international biotechnology business, Biogen was established in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Reward winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medications to deal with numerous sclerosis, has actually presented the very first accepted treatment for spine muscular atrophy, advertises biosimilars of sophisticated biologics and is concentrated on advancing research study programs in numerous sclerosis and neuroimmunology, Alzheimer’s illness and dementia, neuromuscular conditions, motion conditions, ophthalmology, neuropsychiatry, immunology, intense neurology and neuropathic discomfort.

Biogen Safe Harbor

This press release includes positive declarations, consisting of declarations connecting to the prepared for Settlement Date, the prospective consummation of the Money Deal and the Exchange Deal, and the aggregate quantity of money that will be paid on the Settlement Date. These positive declarations might be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” “would” and other words and regards to comparable significance. You must not position excessive dependence on these declarations.

These declarations include threats and unpredictabilities that might trigger real outcomes to vary materially from those shown in such declarations, consisting of the danger that the Exchange Deal is not consummated, the danger that the Money Deal will not be consummated on the terms state in the Money Deal Files or at all, the danger that the Settlement Date might be postponed, the danger that the aggregate quantity of money that will be paid on the Settlement Date might alter, the danger that the Money Deal might be negatively impacted by market conditions or unfavorable modifications to our service or potential customers and the other threats and unpredictabilities that are explained in the Threat Aspects area of our latest yearly or quarterly report and in other reports we have actually submitted with the U.S. Securities and Exchange Commission.

These declarations are based upon present beliefs and expectations and speak just since the date of this press release. We do not carry out any responsibility to openly upgrade any positive declarations.

Biogen Media Contact: Biogen Financier Contact:
David Caouette Mike Hencke
Biogen Inc. Biogen Inc.
Tel: (781) 464-3260 Tel: (781) 464-2442

Primary Logo

Jobber Wiki author Frank Long contributed to this report.